Inhibition of the Raf-1 kinase inhibitory protein (RKIP) by locostatin induces cell death and reduces the CXCR4-mediated migration of chronic lymphocytic leukemia cells

References

• Shustik C, Bence-Bruckler I, Delage R, et al. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Ann Hematol. 2017;96:1185–1196.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Rothstein TL. B cell receptor (BCR) cross-talk: CD40 engagement creates an alternate pathway for BCR signaling that activates I kappa B kinase/I kappa B alpha/NF-kappa B without the need for PI3K and phospholipase C gamma. J Immunol. 2005;174:6062–6070.
   PubMed Web of Science ®Google Scholar
• Steelman LS, Abrams SL, Shelton JG, et al. Dominant roles of the Raf/MEK/ERK pathway in cell cycle progression, prevention of apoptosis and sensitivity to chemotherapeutic drugs. Cell Cycle. 2010;9:1629–1638.
   PubMed Web of Science ®Google Scholar
• Messmer D, Fecteau JF, O'Hayre M, et al. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood. 2011;117:882–889.
   PubMed Web of Science ®Google Scholar
• Yeung KC, Rose DW, Dhillon AS, et al. Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol Cell Biol. 2001;21:7207–7217.
   PubMed Web of Science ®Google Scholar
• Ribas C, Penela P, Murga C, et al. The G protein-coupled receptor kinase (GRK) interactome: role of GRKs in GPCR regulation and signaling. Biochim Biophys Acta. 2007;1768:913–922.
   PubMed Web of Science ®Google Scholar
• Lorenz K, Lohse MJ, Quitterer U. Protein kinase C switches the Raf kinase inhibitor from Raf-1 to GRK-2. Nature. 2003;426:574–579.
   PubMed Web of Science ®Google Scholar
• Lamiman K, Keller JM, Mizokami A, et al. Survey of Raf kinase inhibitor protein (RKIP) in multiple cancer types. Crit Rev Oncog. 2014;19:455–468.
   PubMedGoogle Scholar
• Escara-Wilke J, Keller JM, Ignatoski KM, et al. Raf kinase inhibitor protein (RKIP) deficiency decreases latency of tumorigenesis and increases metastasis in a murine genetic model of prostate cancer. Prostate. 2015;75:292–302.
   PubMed Web of Science ®Google Scholar
• Cross-Knorr S, Lu S, Perez K, et al. RKIP phosphorylation and STAT3 activation is inhibited by oxaliplatin and camptothecin and are associated with poor prognosis in stage II colon cancer patients. BMC Cancer. 2013;13:463.
   PubMed Web of Science ®Google Scholar
• Lee SJ, Lee SH, Yoon MH, et al. A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation. Neoplasia. 2013;15:727–737.
   PubMed Web of Science ®Google Scholar
• Jazirehi AR, Vega MI, Chatterjee D, et al. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab. Cancer Res. 2004;64:7117–7126.
   PubMed Web of Science ®Google Scholar
• Crassini K, Stevenson WS, Mulligan SP, et al. The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine. Leuk Lymphoma. 2015;56:3407–3417.
   PubMed Web of Science ®Google Scholar
• Cossarizza A, Kalashnikova G, Grassilli E, et al. Mitochondrial modifications during rat thymocyte apoptosis: a study at the single cell level. Exp Cell Res. 1994;214:323–330.
   PubMed Web of Science ®Google Scholar
• Dicker F, Schnittger S, Haferlach T, et al. Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood. 2006;108:3152–3160.
   PubMed Web of Science ®Google Scholar
• Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood. 2009;114:4441–4450.
   PubMed Web of Science ®Google Scholar
• Vogler M, Butterworth M, Majid A, et al. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood. 2009;113:4403–4413.
   PubMed Web of Science ®Google Scholar
• Natoni A, O'Dwyer M, Santocanale C. A cell culture system that mimics chronic lymphocytic leukemia cells microenvironment for drug screening and characterization. Methods Mol Biol. 2013;986:217–226.
   PubMedGoogle Scholar
• Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999;94:3658–3667.
   PubMed Web of Science ®Google Scholar
• Corbit KC, Trakul N, Eves EM, et al. Activation of Raf-1 signaling by protein kinase C through a mechanism involving Raf kinase inhibitory protein. J Biol Chem. 2003;278:13061–13068.
   PubMed Web of Science ®Google Scholar
• Abrams ST, Lakum T, Lin K, et al. B-cell receptor signaling in chronic lymphocytic leukemia cells is regulated by overexpressed active protein kinase CbetaII. Blood. 2007;109:1193–1201.
   PubMed Web of Science ®Google Scholar
• Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017;123:2268–2273.
   PubMed Web of Science ®Google Scholar
• Dai H, Chen H, Liu W, et al. Effects of Raf kinase inhibitor protein expression on pancreatic cancer cell growth and motility: an in vivo and in vitro study. J Cancer Res Clin Oncol. 2016;142:2107–2117.
   PubMed Web of Science ®Google Scholar
• Li B, Sun B, Zhu J, et al. Expression of RKIP in chronic myelogenous leukemia K562 cell and inhibits cell proliferation by regulating the ERK/MAPK pathway. Tumour Biol. 2014;35:10057–10066.
   PubMedGoogle Scholar
• Wang A, Duan G, Zhao C, et al. Reduced RKIP expression levels are associated with frequent non-small cell lung cancer metastasis and STAT3 phosphorylation and activation. Oncol Lett. 2017;13:3039–3045.
   PubMed Web of Science ®Google Scholar
• Kleibeuker W, Jurado-Pueyo M, Murga C, et al. Physiological changes in GRK2 regulate CCL2-induced signaling to ERK1/2 and Akt but not to MEK1/2 and calcium. J Neurochem. 2008;104:979–992.
   PubMed Web of Science ®Google Scholar
• Liu S, Premont RT, Kontos CD, et al. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med. 2005;11:952–958.
   PubMed Web of Science ®Google Scholar
• Shvartsur A, Givechian KB, Garban H, et al. Overexpression of RKIP and its cross-talk with several regulatory gene products in multiple myeloma. J Exp Clin Cancer Res. 2017;36:62.
   PubMed Web of Science ®Google Scholar
• El-Gamal D, Williams K, LaFollette TD, et al. PKC-beta as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL. Blood. 2014;124:1481–1491.
   PubMed Web of Science ®Google Scholar
• Winqvist M, Mozaffari F, Palma M, et al. Phase I-II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. Cancer Immunol Immunother. 2017;66:91–102.
   PubMed Web of Science ®Google Scholar
• Liu FT, Jia L, Wang P, et al. STAT3 and NF-kappaB cooperatively control in vitro spontaneous apoptosis and poor chemo-responsiveness in patients with chronic lymphocytic leukemia. Oncotarget. 2016;7:32031–32045.
   PubMedGoogle Scholar
• Yousuf S, Duan M, Moen EL, et al. Raf kinase inhibitor protein (RKIP) blocks signal transducer and activator of transcription 3 (STAT3) activation in breast and prostate cancer. PLoS One. 2014;9:e92478.
   PubMed Web of Science ®Google Scholar
• Muzio M, Scielzo C, Bertilaccio MT, et al. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144:507–516.
   PubMed Web of Science ®Google Scholar